WO2005030239A3 - Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor - Google Patents

Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor Download PDF

Info

Publication number
WO2005030239A3
WO2005030239A3 PCT/JP2004/014451 JP2004014451W WO2005030239A3 WO 2005030239 A3 WO2005030239 A3 WO 2005030239A3 JP 2004014451 W JP2004014451 W JP 2004014451W WO 2005030239 A3 WO2005030239 A3 WO 2005030239A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
topoisomerase
histone deacetylase
antitumor agent
antitumor
Prior art date
Application number
PCT/JP2004/014451
Other languages
French (fr)
Other versions
WO2005030239A2 (en
Inventor
Yoshinori Naoe
Yuka Sasakawa
Original Assignee
Astellas Pharma Inc
Yoshinori Naoe
Yuka Sasakawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Yoshinori Naoe, Yuka Sasakawa filed Critical Astellas Pharma Inc
Priority to CA002540108A priority Critical patent/CA2540108A1/en
Priority to DE602004027824T priority patent/DE602004027824D1/en
Priority to AT04773539T priority patent/ATE471740T1/en
Priority to EP04773539A priority patent/EP1670514B1/en
Priority to PL04773539T priority patent/PL1670514T3/en
Priority to JP2006515402A priority patent/JP4779971B2/en
Priority to MXPA06003222A priority patent/MXPA06003222A/en
Publication of WO2005030239A2 publication Critical patent/WO2005030239A2/en
Publication of WO2005030239A3 publication Critical patent/WO2005030239A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to an antitumor agent containing a histone deacetylase inhibitor and a topoisomerase II inhibitor in combination, and an enhancer of antitumor effect of topoisomerase II inhibitor, which contains a histone deacetylase inhibitor as an active ingredient. The present invention provides an antitumor agent having superior antitumor activity, which is associated with a fewer side effects.
PCT/JP2004/014451 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor WO2005030239A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002540108A CA2540108A1 (en) 2003-09-25 2004-09-24 Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
DE602004027824T DE602004027824D1 (en) 2003-09-25 2004-09-24 ANTITUMORAL AGENT WITH A HISTON DEACETYLASE INHIBITOR AND A TOPOISOMERASE II HEMMER
AT04773539T ATE471740T1 (en) 2003-09-25 2004-09-24 ANTITUMORAL AGENT CONTAINING A HISTONE DEACETYLASE INHIBITOR AND A TOPOISOMERASE II INHIBITOR
EP04773539A EP1670514B1 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
PL04773539T PL1670514T3 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
JP2006515402A JP4779971B2 (en) 2003-09-25 2004-09-24 Antitumor agent comprising histone deacetylase inhibitor and topoisomerase II inhibitor
MXPA06003222A MXPA06003222A (en) 2003-09-25 2004-09-24 Antimutor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003-334340 2003-09-25
JP2003334340 2003-09-25
JP2003-344315 2003-10-02
JP2003344315 2003-10-02

Publications (2)

Publication Number Publication Date
WO2005030239A2 WO2005030239A2 (en) 2005-04-07
WO2005030239A3 true WO2005030239A3 (en) 2005-07-28

Family

ID=34380371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/014451 WO2005030239A2 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor

Country Status (14)

Country Link
US (1) US7314862B2 (en)
EP (2) EP2263694B1 (en)
JP (1) JP4779971B2 (en)
AT (1) ATE471740T1 (en)
CA (1) CA2540108A1 (en)
CY (1) CY1114359T1 (en)
DE (1) DE602004027824D1 (en)
DK (1) DK2263694T3 (en)
ES (2) ES2344899T3 (en)
MX (1) MXPA06003222A (en)
PL (2) PL2263694T3 (en)
PT (1) PT2263694E (en)
SI (1) SI2263694T1 (en)
WO (1) WO2005030239A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298414C2 (en) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Medicinal use of histon deacetylase inhibitor and method for assay of its anti-tumor effect
CA2481466A1 (en) * 2002-04-05 2003-10-16 Yoshinori Naoe Depsipeptide for therapy of kidney cancer
JPWO2004074478A1 (en) * 2003-02-19 2006-06-01 アステラス製薬株式会社 Prediction method of antitumor effect of histone deacetylase inhibitor
JP2006520796A (en) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
EP2263694B1 (en) 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007011626A2 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007040522A1 (en) * 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
EP1965824A4 (en) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc Metabolite derivatives of the hdac inhibitor fk228
JP2009525955A (en) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
PT2099442E (en) * 2006-12-26 2015-02-10 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
CN101687010A (en) * 2006-12-29 2010-03-31 格洛斯特制药公司 Romidepsin preparation
US8034768B2 (en) * 2007-06-22 2011-10-11 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
EP2257310A2 (en) * 2008-02-26 2010-12-08 Nerviano Medical Sciences S.r.l. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
SG2014014419A (en) 2011-09-13 2014-07-30 Pharmacyclics Inc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2915536B1 (en) * 2012-11-01 2019-08-21 Microbial Chemistry Research Foundation Anticancer agent, and combination use anticancer agent
CN116327887B (en) * 2023-04-24 2023-11-03 南京捷因诊断技术有限公司 Application of LSD1 inhibitor as antitumor drug

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
EP1302476A1 (en) * 2000-07-17 2003-04-16 Fujisawa Pharmaceutical Co., Ltd. Reduced fk228 and use thereof
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
WO2004103369A1 (en) * 2003-05-26 2004-12-02 Schering Aktiengesellschaft Pharmaceutical composition containing histone deacetylase inhibitor

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
US486379A (en) * 1892-11-15 Hame-tug
US3997633A (en) * 1975-06-24 1976-12-14 Max Leva Contact towers with leak-proof support of improved plate subassembly
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348388A (en) * 1980-04-02 1982-09-07 G.D. Searle & Co. 11-Amino-11-deoxydaunorubicin and analogs
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4950755A (en) * 1985-08-12 1990-08-21 Ohio State University Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane
US5242901A (en) * 1988-01-27 1993-09-07 New York University Reduction of anthracycline induced cardiotoxicity
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH05507480A (en) * 1990-05-26 1993-10-28 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 1,4-dihydropyridine for use in overcoming drug resistance
US5620961A (en) * 1994-04-25 1997-04-15 Markovic; Nenad S. Fructose ester-β-cyclodextrin complexes and processes for making and using same
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
CA2275889C (en) * 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6286513B1 (en) * 1998-10-22 2001-09-11 Jessie L. Au Methods for treating superficial bladder carcinoma
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
DK1233958T3 (en) * 1999-11-23 2011-10-17 Methylgene Inc Inhibitors of histone deacetylase
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
ATE470447T1 (en) 1999-12-08 2010-06-15 Cyclacel Pharmaceuticals Inc DEPSIPETIDE AND CONGENERS THEREOF FOR USE AS IMMUNOSUPRESSIVES FOR THE PREVENTION AND TREATMENT OF REJECTION REACTIONS AS A RESULT OF TRANSPLANTATION AND FOR THE INDUCTION OF APOPTOSIS IN ACTIVATED CD4 OR CD8 T CELLS
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
HUP0302599A3 (en) * 2000-09-22 2005-05-30 Bristol Myers Squibb Co Method for reducing toxicity of combined chemotherapic compositions
WO2002024178A2 (en) * 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
WO2002045717A1 (en) * 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
WO2002059375A2 (en) * 2001-01-26 2002-08-01 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
WO2002076472A2 (en) * 2001-03-23 2002-10-03 Shire Biochem Inc. Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
RU2298414C2 (en) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Medicinal use of histon deacetylase inhibitor and method for assay of its anti-tumor effect
CA2481466A1 (en) * 2002-04-05 2003-10-16 Yoshinori Naoe Depsipeptide for therapy of kidney cancer
CA2486124A1 (en) * 2002-05-17 2003-11-27 Aventis Pharma S.A. Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2004034876A2 (en) * 2002-10-15 2004-04-29 Ferx Incorporated Magnetically guided particles for radiative therapies
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
ES2341771T3 (en) * 2003-06-27 2010-06-28 Astellas Pharma Inc. THERAPEUTIC AGENT AGAINST THE SOFT TISSUE SARCOMA.
EP2263694B1 (en) 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302476A1 (en) * 2000-07-17 2003-04-16 Fujisawa Pharmaceutical Co., Ltd. Reduced fk228 and use thereof
WO2002085400A1 (en) * 2001-04-24 2002-10-31 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
WO2004064727A2 (en) * 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
WO2004103358A2 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
WO2004103369A1 (en) * 2003-05-26 2004-12-02 Schering Aktiengesellschaft Pharmaceutical composition containing histone deacetylase inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM MYOUNG SOOK ET AL.: "Inhibition of histone deacetylase increases topoisomerase inhibitors efficiency in cells clinically resistant to Top2 inhibitors", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 43, March 2002 (2002-03-01), pages 510 - 511, XP001205058 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539303B2 (en) 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US9259452B2 (en) 2006-06-08 2016-02-16 Gelgene Corporation Deacetylase inhibitor therapy
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US8980825B2 (en) 2010-07-12 2015-03-17 Celgene Corporation Romidepsin solid forms and uses thereof
US9518094B2 (en) 2010-07-12 2016-12-13 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9134325B2 (en) 2012-09-07 2015-09-15 Celgene Corporation Resistance biomarkers for HDAC inhibitors
US9101579B2 (en) 2012-11-14 2015-08-11 Celgene Corporation Inhibition of drug resistant cancer cells
US9463215B2 (en) 2013-12-27 2016-10-11 Celgene Corporation Romidepsin formulations and uses thereof
US9468664B2 (en) 2013-12-27 2016-10-18 Celgene Corporation Romidepsin formulations and uses thereof

Also Published As

Publication number Publication date
EP1670514B1 (en) 2010-06-23
US7314862B2 (en) 2008-01-01
WO2005030239A2 (en) 2005-04-07
MXPA06003222A (en) 2006-05-22
PT2263694E (en) 2013-08-27
ATE471740T1 (en) 2010-07-15
EP1670514A2 (en) 2006-06-21
JP4779971B2 (en) 2011-09-28
EP2263694B1 (en) 2013-06-12
US20050070467A1 (en) 2005-03-31
JP2007506647A (en) 2007-03-22
ES2425083T3 (en) 2013-10-11
DK2263694T3 (en) 2013-08-26
CA2540108A1 (en) 2005-04-07
ES2344899T3 (en) 2010-09-09
DE602004027824D1 (en) 2010-08-05
PL1670514T3 (en) 2010-11-30
PL2263694T3 (en) 2013-11-29
SI2263694T1 (en) 2013-09-30
CY1114359T1 (en) 2016-08-31
EP2263694A1 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
WO2005030239A3 (en) Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
WO2005079827A3 (en) Antitumor agent
WO2006015159A3 (en) Potassium channel inhibitors
WO2003080070A3 (en) Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
WO2005066151A3 (en) Histone deacetylase inhibitors
WO2003077723A3 (en) Methods and devices for detection and therapy of atheromatous plaque
EP1550448A4 (en) Histamine release inhibitor
WO2005030129A3 (en) Quinoline potassium channel inhibitors
EP2607348A3 (en) Plasminogen Activator Inhibitor-1 Inhibitor
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2007076028A3 (en) Insecticidal and miticidal mixtures of bifenthrin and cyano-pyrethroids
EP2913322A3 (en) Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2007050348A3 (en) Potassium channel inhibitors
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
MXPA05012753A (en) Stable cosmetic compositions comprising a self-tanning agent.
AU2003277721A1 (en) Beta-nitrostyrene compound and telomerase inhibitor having an anticancer activity
WO2007022219A3 (en) Dental composition comprising enzyme
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2004091591A3 (en) Nutritional or therapeutic composition containing the compound oleuropeine or one of the derivatives thereof
WO2006042625A3 (en) Compositions with inhibitors of the synthesis of prostaglandin and/or of leukotriene in conjunction with stimulators of the release of cutaneous neuromediators
AU2002330850A1 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
WO2002030941A3 (en) Topoisomerase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004773539

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/003222

Country of ref document: MX

Ref document number: 2540108

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006515402

Country of ref document: JP

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWP Wipo information: published in national office

Ref document number: 2004773539

Country of ref document: EP